Investors Purchase High Volume of Aimmune Therapeutics Call Options (NASDAQ:AIMT)

Aimmune Therapeutics Inc (NASDAQ:AIMT) was the target of unusually large options trading on Thursday. Investors purchased 10,273 call options on the stock. This is an increase of 1,387% compared to the typical daily volume of 691 call options.

Shares of AIMT opened at $26.47 on Friday. The business’s 50 day moving average is $22.98 and its 200 day moving average is $20.86. Aimmune Therapeutics has a 12-month low of $16.95 and a 12-month high of $36.12. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.08). During the same quarter in the prior year, the company earned ($0.91) earnings per share. As a group, sell-side analysts anticipate that Aimmune Therapeutics will post -4 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on the company. Royal Bank of Canada lowered their price objective on Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. BidaskClub raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, October 10th. Stifel Nicolaus raised Aimmune Therapeutics to a “positive” rating in a research report on Monday, September 16th. Wedbush reaffirmed an “outperform” rating and set a $79.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, September 16th. Finally, Roth Capital assumed coverage on Aimmune Therapeutics in a research report on Friday, July 12th. They set a “buy” rating and a $45.00 price objective on the stock. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.11.

In other news, CFO Eric Bjerkholt bought 1,550 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were acquired at an average cost of $22.57 per share, with a total value of $34,983.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 13.75% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in Aimmune Therapeutics by 11.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock valued at $109,234,000 after purchasing an additional 535,072 shares during the period. Vanguard Group Inc. raised its stake in Aimmune Therapeutics by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock valued at $77,167,000 after purchasing an additional 164,038 shares during the period. FMR LLC raised its stake in Aimmune Therapeutics by 30.3% during the 1st quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock valued at $61,117,000 after purchasing an additional 635,362 shares during the period. Victory Capital Management Inc. increased its stake in Aimmune Therapeutics by 2.4% in the 2nd quarter. Victory Capital Management Inc. now owns 1,121,811 shares of the biotechnology company’s stock worth $23,357,000 after acquiring an additional 26,690 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in Aimmune Therapeutics by 31.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 669,560 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 158,851 shares during the last quarter. 78.09% of the stock is currently owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: Marijuana Stocks Future Looks Bright

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.